Edwards Lifesciences Corp (NYSE:EW) CEO Michael A. Mussallem sold 22,850 shares of the business’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $184.27, for a total transaction of $4,210,569.50. Following the completion of the transaction, the chief executive officer now owns 95,770 shares in the company, valued at approximately $17,647,537.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
NYSE EW traded down $0.80 on Wednesday, hitting $184.80. The stock had a trading volume of 1,055,118 shares, compared to its average volume of 1,270,799. Edwards Lifesciences Corp has a 52-week low of $134.53 and a 52-week high of $197.86. The company has a debt-to-equity ratio of 0.19, a current ratio of 3.66 and a quick ratio of 2.69. The stock has a market capitalization of $38.07 billion, a PE ratio of 39.32, a P/E/G ratio of 2.35 and a beta of 0.85.
Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, April 23rd. The medical research company reported $1.32 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.23 by $0.09. Edwards Lifesciences had a net margin of 20.03% and a return on equity of 31.16%. The business had revenue of $993.00 million for the quarter, compared to analysts’ expectations of $989.87 million. During the same period in the prior year, the company posted $1.22 EPS. The business’s revenue for the quarter was up 11.0% compared to the same quarter last year. On average, research analysts anticipate that Edwards Lifesciences Corp will post 5.29 EPS for the current year.
Several brokerages have recently weighed in on EW. Stifel Nicolaus upped their price objective on shares of Edwards Lifesciences from $190.00 to $200.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Jefferies Financial Group upped their price objective on shares of Edwards Lifesciences from $195.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Credit Suisse Group increased their target price on shares of Edwards Lifesciences from $189.00 to $221.00 and gave the company an “outperform” rating in a research report on Monday, April 15th. JPMorgan Chase & Co. upped their price target on shares of Edwards Lifesciences from $175.00 to $190.00 and gave the company a “neutral” rating in a research note on Wednesday, March 27th. They noted that the move was a valuation call. Finally, BMO Capital Markets upped their price target on shares of Edwards Lifesciences to $204.00 and gave the company an “outperform” rating in a research note on Friday, March 22nd. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $186.52.
Hedge funds and other institutional investors have recently bought and sold shares of the business. FTB Advisors Inc. purchased a new stake in Edwards Lifesciences in the 1st quarter worth approximately $25,000. Executive Wealth Management LLC purchased a new stake in Edwards Lifesciences in the 4th quarter worth approximately $25,000. Sontag Advisory LLC purchased a new stake in Edwards Lifesciences in the 4th quarter worth approximately $26,000. Field & Main Bank purchased a new stake in Edwards Lifesciences in the 1st quarter worth approximately $34,000. Finally, Lindbrook Capital LLC purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $27,000. Institutional investors and hedge funds own 82.12% of the company’s stock.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Featured Story: Exchange-Traded Funds (ETFs)
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.